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A b s t r A c t
A 45-year-old woman developed exertional dyspnea after surgical removal of uterine 
fibroids. Cardiac ultrasound showed right ventricular dilation and dysfunction due 
to pulmonary arterial hypertension, whereas subsequent computed tomography (CT) 
angiography revealed pulmonary embolism. Anticoagulant therapy was initiated. Per-
fusion defects were noticeable in lung perfusion scan 6 months after the initiation of 
anticoagulant therapy, while CT angiography was negative for pulmonary embolism. 
The diagnosis of chronic thromboembolic pulmonary hypertension was initially en-
tertained and subsequently confirmed by right heart catheterization. Deterioration of 
dyspnea and right ventricular dysfunction led to administration of intravenous epo-
prostenol through an indwelling central venous catheter. After 6 months, the patient 
was admitted to the intensive care unit with fever, hemoptysis, lung infiltrates, and 
acute-on-chronic hypoxemic respiratory failure. Bronchial artery embolization, oxy-
gen therapy, and antibiotics led to clinical improvement.
I n t r o d u c t I o n
According to the latest clinical classification, chronic thromboembolic pulmonary 
hypertension (CTEPH) belongs to group 4 of pulmonary hypertension.1,2 The hemody-
namic classification places CTEPH in the pre-capillary pulmonary hypertension group.1 
A clinical event of pulmonary embolism is not compulsory and nearly half the patients 
with CTEPH do not report one.3 CTPEH may progress regardless of antithrombotic 
therapy since a vascular remodeling cascade is initiated after a thrombotic insult.1 
Ventilation/perfusion scan (V/Q scan) provides the highest sensitivity and specificity 
and is indispensable in the diagnostic algorithm of pulmonary hypertension to safely 
exclude or confirm CTPEH.1 Therapy may comprise agents used to treat primary 
or idiopathic pulmonary arterial hypertension. Intravenous vasodilator agents are 
reserved for patients with advanced functional incapacity1 and their administration 
through central venous catheters increases the risk of bloodstream infections.4 Another 
potentially lethal complication is hemoptysis, with bronchial artery embolization being 
an effective and safe treatment.5,6
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c A s e  r e p o r t
A 45-year-old woman developed exertional dyspnea after 
surgical removal of uterine fibroids. Her past medical history 
included splenectomy at the age of 2 years due to leishmani-
asis, heterozygous beta-thalassemia, and active smoking of 30 
pack-years. She was mother to two healthy children. Cardiac 
ultrasound revealed right ventricular enlargement and dys-
function compatible with the presence of pulmonary arterial 
hypertension. Computer tomography (CT) angiography was 
positive for pulmonary embolism (Fig. 1) and anticoagulant 
therapy was initiated.
Six months after the initiation of anticoagulant therapy 
with a vitamin K antagonist and while the international 
normalized ratio (INR) was in the therapeutic range (2-3),1 
patient’s exertional dyspnea substantially increased. Follow-up 
echocardiography showed that the systolic function of the right 
ventricle had deteriorated and the pressure in the pulmonary 
artery was further increased. Patient was suffering from re-
spiratory failure and supplemental oxygen was administered. 
CT angiography was negative for pulmonary embolism, and 
the lung perfusion scan revealed multiple perfusion defects 
(Fig. 2). The diagnosis of pulmonary arterial hypertension due 
to CTEPH was initially entertained. Patient was started on 
diuretics (furosemide), digoxin, and an endothelin-antagonist 
(bosentan).
In order to further confirm the diagnosis of CTEPH, and 
because the patient’s functional status continued to deteriorate 
despite treatment, right heart catheterization was performed. 
Measurements revealed pre-capillary pulmonary hyperten-
sion, with a mean pulmonary artery pressure (PAP) of 65 
mmHg. The vasoreactivity test performed with intravenous 
administration of epoprostenol showed a positive response,1 
with a mean PAP reduction >10 mmHg reaching a value of 
40 mmHg without decreasing cardiac output (Table 1). The 
FIgure 1. Computed tomography pulmonary angiography 
shows bilateral pulmonary emboli (arrows).
FIgure 2. Lung perfusion scan with multiple perfusion defects. 
CT pulmonary angiography performed at the same time was 
negative for pulmonary embolism.
tAble 1. Right heart catheterization measurements
Hemodynamic parameters obtained values normal values8 Values obtained after the vasoreactivity test
Systolic pulmonary artery pressure (mmHg) 109 <30 60
Diastolic pulmonary artery pressure (mmHg) 40 <12 20
Mean pulmonary artery pressure (mmHg) 65 <20 40
Pulmonary capillary wedge pressure (mmHg) 8 2-15 8
Pulmonary vascular resistance (Wood units) 16 <2 7.4
Cardiac index (L/min/m2) 2.2 2.5 – 4.0 2.7
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patient was unable to carry out her daily activities and started 
feeling breathless at rest. She was classified as functional 
class 4 according to World Health Organization functional 
classification (WHO-FC),7 and administration of intravenous 
epoprostenol through an indwelling central venous catheter 
(Hickman) was started.
At 6 months later, the patient was admitted to the intensive 
care unit (ICu) due to severe acute-on-chronic hypoxemic 
respiratory failure and high fever. Laboratory findings were 
remarkable for an elevated C-reactive protein (5.1 mg/dl; 
normal values <0.3 mg/dl) and white blood cell count (17.000/
μL; 80% neutrophils). Arterial blood gas examination showed 
hypoxemia (pO2 58 mmHg, pCO2 28 mmHg, pH 7.51, HCO3 
26 mmol/L, O2 saturation 91%), while the patient was receiv-
ing 100% fraction of inspired oxygen (FIO2) administered via 
a full-face reservoir oxygen mask. Patient’s fever pattern was 
characterized by two febrile waves per day for the preceding 
8 days. Chest CT revealed multiple lung infiltrates (Fig. 3).
Seven days after ICu admission, repeated episodes of 
hemoptysis led to clinical deterioration and anticoagula-
tion therapy had to be suspended. Multi-resistant Klebsiella 
pneumonia, sensitive only to gentamycin, tigecycline and the 
combination of meropenem and colimycin, was isolated from 
a blood culture that was drawn through the Hickman catheter. 
The blood culture from a peripheral vein that was taken si-
multaneously was negative and the catheter entry site had no 
indication of skin inflammation. A coronavirus was detected 
in patient’s sputum with polymerase chain reaction. Repeated 
sets of blood cultures drawn from the Hickman catheter and 
periphery were also negative and no other pathogen was 
detected from sputum, urine and blood through cultures and 
molecular techniques. Transthoracic echocardiogram was neg-
ative for endocarditis and confirmed right ventricular dilation 
and dysfunction, and severe pulmonary hypertension. Trans-
esophageal echocardiography could not be performed due to 
patient’s respiratory status with marginal blood oxygenation 
(O2 saturation 93%) despite administration of 100% oxygen. 
The left internal jugular vein, were the Hickman catheter was 
placed, was free of thrombus.
A second central venous catheter was placed via the right 
internal jugular vein for epoprostenol administration and the 
Hickman catheter was locked with a concentrated mixture of 
gentamycin and heparin that was renewed every 48 hours for 
7 days. Systemic antibiotics were also administrated. Notably, 
patient’s hemodynamic status was rather stable, and no inotro-
pic drug infusion (dobutamine or noradrenaline) was required. 
Hemoptysis was successfully treated with embolization of a 
hypertrophic supernumerary bronchial artery (Fig. 4), and 
anticoagulation was promptly reinitiated. Respiratory failure 
progressively improved, fever subsided, and lung infiltrates 
gradually resolved. The Hickman catheter was again used for 
the continuous administration of epoprostenol, and the right 
internal jugular venous catheter was removed. The patient 
was discharged after a 30-day stay in the ICu, afebrile, with 
continuous oxygen administration through a nasal cannula (~2 
L/minute). Arterial blood gas examination reveal a pO2 of 65 
mmHg, a pCO2 of 33 mmHg, a pH of 7.47, and a bicarbonate 
level of 25 mmol/L. The patient was subsequently referred to 
a specialized center to be evaluated for lung transplantation.
d I s c u s s I o n
Chronic thromboembolic pulmonary hypertension 
(CTEPH) accounts for less than 1% of all cases of pulmonary 
hypertension, while left heart disease accounts for the majority 
FIgure 3. CT of the chest showing multiple ground glass infil-
trates (arrows).
FIgure 4. Embolization of a hypertrophic supernumerary right 
bronchial artery that was considered the origin of hemoptysis 
(the arrow on the left indicates the picture before and the arrow 
on the right the image after embolization).
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of these cases, around 80%.9 CTEPH may complicate up to 
3.8% of acute pulmonary embolic events,10 yet most experts 
believe this rather occurs at lower rates (0.5-2%).1 Certain 
medical conditions are associated with an increased risk of 
CTEPH, including myeloproliferative disorders, chronic in-
flammatory bowel disease, and previous splenectomy.11 Our 
patient had undergone splenectomy when she was 2 years-old.
Persistent pulmonary artery hypertension and/or right 
ventricular dysfunction following pulmonary embolism should 
raise the suspicion for CTEPH. Additionally, the differential 
diagnosis of “unexplained” pulmonary hypertension should 
definitely include CTEPH.1 Ventilation/perfusion (V/Q) 
scan remains the cornerstone for the diagnosis of CTEPH. 
Despite the technological advances in CT imaging, V/Q scan 
yields higher specificity and sensitivity.1 Indeed, our patient 
was suffering from CTEPH, but the follow-up CT angiogra-
phy was negative for pulmonary embolism, whereas the lung 
perfusion scan revealed unmatched perfusion defects (Figure 
2). A normal or low probability V/Q scan may safely exclude 
CTEPH.1 Nevertheless, right heart catheterization is required 
to establish the diagnosis of CTEPH by the presence of pre-
capillary pulmonary hypertension (mean PAP >25 mmHg) in 
conjunction with unmatched perfusion defects or organized 
thrombi attached to the pulmonary artery.1
The pathobiology of CTEPH is not fully elucidated; how-
ever, the mechanical obstructions by persistent embolic masses 
that adhere to the pulmonary vascular bed in conjunction with 
abnormalities in the coagulation cascade play a pivotal role.1 
Thrombus formation in the pulmonary vascular bed and the 
subsequent rise in pulmonary arterial pressure may trigger 
vascular remodeling leading to a self-sustained pulmonary 
hypertension without further provision of thrombotic mate-
rial.12,13 Vessel changes are not confined to pulmonary arteries. 
Indeed, bronchial artery hypertrophy is reported in nearly 
half the patients with pulmonary artery hypertension (PAH) 
(44%)14 and in the majority of patients with CTEPH (73%).15 
Bronchial artery hypertrophy is linked to hemoptysis and is 
highly prevalent in patients with CTEPH.5 In our case, emboli-
zation of a hypertrophic supernumerary bronchial artery (Fig-
ure 4) safely controlled hemoptysis and obviated intubation, 
which was otherwise imminent, as our patient suffered from 
severe hypoxemia. Bronchial artery embolization is reported 
as the treatment of choice for patients with hemoptysis on the 
ground of pulmonary hypertension.5,6
Lifelong anticoagulant therapy may be necessary, al-
beit not adequate, for all patients with CTEPH.1 Supportive 
therapy for PAH that may also be administered to patients 
with CTEPH includes diuretics, oxygen therapy, and digoxin 
(especially in patients with tachyarrhythmias).1 Surgery may 
help patients with proximal organized thrombi; however, 
proper selection of patients, surgical technique, and post-
operative management in an experienced center dictates 
outcome.16 However, our patient did not have proximal 
organized thrombi, and thus she was rather not eligible for 
pulmonary endarterectomy.
According to the latest guidelines, specific drugs used in 
pulmonary artery hypertension may also be administered to 
patients with CTEPH who are inoperable, or before surgery 
in order to achieve clinical and hemodynamic improvement, 
or after surgery in patients who relapse.1 Our patient was re-
ceiving intravenous epoprostenol due to inoperable CTEPH 
and a WHO functional class 4.7 Epoprostenol is a synthetic 
prostacyclin analogue that is reserved for patients with primary 
pulmonary hypertension in advanced stages (WHO functional 
class 3 and 4), and may be given in addition to other specific 
medications in WHO class 4 when an inadequate clinical re-
sponse is encountered.1 Bosentan is an endothelin antagonist 
that proved to safely decrease pulmonary vascular resistance 
in inoperable patients with CTEPH.17 Nonetheless, patients 
who continue to deteriorate despite treatment and are not 
suited for pulmonary endarterectomy should be evaluated in 
specialized centers for bilateral lung transplant.1 Our patient 
was rather eligible for lung transplant and was referred to a 
specialized center for evaluation of lung transplantation.
Indwelling central venous catheters are frequently colo-
nized with bacteria.18 Indeed, in a study were the microbio-
logical management of tunneled central venous catheters was 
investigated, about 1 out of 4 (26.2%) catheters was colonized 
with bacteria but less than 1 out of 10 (7.4%) was responsible 
for catheter related blood stream infection (CRBSI).18 Patients 
receiving continuous intravenous therapy for PAH are at risk 
of catheter related sepsis, as was shown in the early studies 
that proved epoprostenol’s efficacy and safety.4 According to 
the latest guidelines, a definitive diagnosis of CRBSI requires 
the isolation of the same organism from blood drown from the 
catheter hub and from a peripheral vein through percutaneous 
puncture.19 A threefold greater colony count from catheter 
blood is required when quantitative blood cultures are avail-
able, while in semi-quantitative blood cultures, microorganisms 
in catheter blood should grow at least 2 hours before peripheral 
blood sample.19 Central catheters should be removed if there 
are indications of severe sepsis, suppurative thrombophlebitis, 
endocarditis, or bloodstream infection persists for 72 hours 
after treatment.19 Tunneled central venous catheters should 
also be removed if there are indications of tunnel infection.19 
Accordingly, we decided not to remove the Hickman catheter 
since a definite CRBSI could not be established, catheter tun-
nel and entry site had no pathology, patient was hemodynami-
cally stable, and endocarditis or thrombophlebitis could not be 
detected. However, persistent fever, bilateral lung infiltrates 
and severe hypoxemia led us to administer broad spectrum 
antibiotics also effective against the multi-resistant strain of 
Klebsiella pneumonia cultured from blood drown from the 
Hickman catheter. Probably it was an overtreatment, but it is 
well known that in CTPEH, complications such as CRBSI or 
sepsis may lead to unfavorable outcome and must be promptly 
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treated in fine balance to an overwhelmed cardiopulmonary 
system.4,19 Antibiotic lock was decided in an attempt to salvage 
the possibly colonized Hickman catheter, according to latest 
guidelines.19
Coronaviruses are common viruses that cause mild to 
moderate upper respiratory tract infection and most people 
are infected at least once in their life time. A viral cause was 
established in 366 out of 1029 patients (35.6%) with chronic 
underlying (predominantly pulmonary) conditions hospitalized 
for acute respiratory disease.20 The association of coronavirus 
infection and severe respiratory complications (including 
pneumonia) in adults with underlying cardiopulmonary disease 
is also established.21 Accordingly, we considered the isolated 
coronavirus to be the cause of the multiple infiltrates and 
worsening respiratory failure of our patient. To our knowledge 
there is no special therapy for coronavirus pneumonia22 and 
supportive measures were applied.
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